Antibody-drug conjugates in urothelial carcinomas Review

  


Authors: Sarfaty, M.; Rosenberg, J. E.
Review Title: Antibody-drug conjugates in urothelial carcinomas
Abstract: Purpose of Review: Urothelial carcinoma (UC) is a common malignancy with an urgent need for more effective and less toxic treatment strategies. Antibody-drug conjugate (ADC) represents a novel therapeutic approach, which combines the high specificity of monoclonal antibodies covalently linked with highly active cytotoxic agents. UC is an appropriate candidate for these drugs, as it expresses unique cell surface antigens that allow for specific targeting of these cells. We hereby present a review of the current literature and future perspectives of ADC treatment in early-stage and metastatic UC. Recent Findings: Several ADCs are in advanced stages of development and approval, such as intravesical oportuzumab monatox in BCG-refractory non-muscle invasive bladder cancer and enfortumab vedotin and sacituzumab govitecan in pretreated metastatic UC. Other agents are in earlier stages of development, including some promising anti-Her2 agents. The favorable toxicity profile of these agents led to several combination strategies, especially with checkpoint inhibitors. Summary: In light of the encouraging results presented in this review and the recent FDA approval of enfortumab vedotin, ADCs will likely be incorporated in the management of UC in the near future. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords: cancer chemotherapy; unclassified drug; review; nonhuman; antineoplastic agent; metastasis; bladder cancer; urothelial carcinoma; trastuzumab; transitional cell carcinoma; her2; trastuzumab emtansine; antibody-drug conjugate; human; antibody drug conjugate; nectin-4; trop-2; asg 15 e; asg 15 me; asg 22 ce; asg 22 me; ds 8201 a; enfortumab vedotin; oportuzumab monatox; rc 48 adc; sacituzumab govitecan; trastuzumab deruxtecan; vb 4 845
Journal Title: Current Oncology Reports
Volume: 22
Issue: 2
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2020-02-01
Start Page: 13
Language: English
DOI: 10.1007/s11912-020-0879-y
PUBMED: 32008109
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078855059&doi=10.1007%2fs11912-020-0879-y&partnerID=40&md5=9924f33592bd4e5eed5d0bc8ee8dc075
Notes: Review -- Export Date: 2 March 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg
  2. Michal Sarfaty
    11 Sarfaty
Related MSK Work